SCHEMBL8336385

SCHEMBL8336385

Cc1sc2nc(-c3ccc(C(=O)O)cc3)nc(Cl)c2c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
POLB P06746 3/20 0.45
NPC1 O15118 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
KDM4E B2RXH2 4/20 0.41
GFER P55789 1/20 0.41
FLT3 P36888 1/20 0.40
RAB9A P51151 2/20 0.40
HTT P42858 2/20 0.40
GAA P10253 1/20 0.40
ADORA3 P0DMS8 3/20 0.39
ADORA2A P29274 2/20 0.39
PRKCI P41743 1/20 0.39
ABCB1 P08183 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8339527 0.89 POLB (0.45) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL5119506 0.80 PRKCI (0.57) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL8339222 0.78 KDM4E (0.46) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL8334672 0.76 RARA (0.41) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL8170324 0.75 ALDH1A1 (0.49) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL8180806 0.75 FYN (0.46) ALDH1A1NPC1SMN1; SMN2KDM4EGFER
SCHEMBL8183517 0.75 PRKCI (0.50) ALDH1A1SMN1; SMN2HPGDRARARARB
SCHEMBL8336745 0.74 ABCC1 (0.55) ALDH1A1POLBNPC1SMN1; SMN2HPGD
SCHEMBL8171294 0.74 PRKCI (0.53) ALDH1A1SMN1; SMN2KDM4EHTTPRKCI
SCHEMBL8184718 0.74 FLT3 (0.51) ALDH1A1SMN1; SMN2HPGDKDM4EFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5948911-A Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 1999-09-07 US disclosed